Q2 2026 Arcticzymes Technologies ASA Earnings Call Transcript
Key Points
- Total revenue for Q2 2026 reached NOK 31.9 million, up 19% year-over-year, marking the largest second quarter outside the COVID period.
- Molecular Tools segment delivered a remarkable 84% year-over-year growth in Q2, driven by a broadened customer base and new applications.
- A new CDMO was onboarded for mSAN GMP, leading to an 18-month worldwide supply agreement and first purchase order, expanding GMP footprint.
- A key customer received FDA PMA approval for a cancer screening test, with ArcticZymes' enzyme embedded in the workflow, opening doors to future kits and revenue growth.
- EBITDA more than doubled to NOK 7.4 million in Q2, with margin improving to 23% from 15%, reflecting strong operating leverage and a 95% gross margin.
- The company maintains a robust financial position with NOK 269 million in cash and short-term investments, supporting strategic initiatives.
- Currency headwinds negatively impacted reported revenue, with constant currency growth at 29% versus reported 19% in Q2.
- Biomanufacturing segment revenue declined 12% year-over-year due to tough comparatives and softness in a few accounts in one territory.
- CDMO customers are becoming more cautious with spending due to tighter milestone requirements, potentially affecting order patterns.
- Quarterly revenue volatility persists due to dependence on large orders, though the company is working to diversify its customer base.
- Personnel expenses increased 18% year-over-year, reflecting higher bonus accruals and full effect of commercial hires, which could pressure margins if revenue growth slows.
Good morning and welcome to ArcticSymes Q2 2026 report. My name is Michael Akoh. I'm the CEO of ArcticSymes, and I'm as usual joined by our CFO, Bergen Serval, as well as our CCO, Paul Blackburn. Let's take a look at our agenda today.
We're going to start off by looking into the Q2 highlights as well as a recap of our strategy.
Then Paul is going to go through an interesting commercial update. He's going to look at the numbers for our two segments, but he's also going to focus on a couple of customer cases.
Then Berger is going to go through our financial performance, and I'm going to come back and look a bit into the future, recap our ambition.
And do a general summary of today's presentation.
And last but not least, we're going to look into the questions that you might have after today's presentation.
But let's get started.
We had a good strong start to the year. We've had a good first half and the business is in general in a good place today.
We had a total
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
